AB Science Valuation
Is A8D undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of A8D when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate A8D's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate A8D's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for A8D?
Key metric: As A8D barely has revenue we use its Price-To-Book Ratio for relative valuation analysis.
| What is A8D's PB Ratio? | |
|---|---|
| PB Ratio | -3.1x |
| Book | -€27.32m |
| Market Cap | €84.33m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 95.8x |
| Enterprise Value/EBITDA | -20.9x |
| PEG Ratio | n/a |
Price to Book Ratio vs Peers
How does A8D's PB Ratio compare to its peers?
| Company | Forward PB | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 1.4x | ||
APPH Apontis Pharma | 2.9x | 115.01% | €91.6m |
HIGH Cantourage Group | 0.8x | 87.02% | €36.7m |
93M1 MPH Health Care | 0.4x | 139.82% | €74.3m |
NV5 AcuCort | 1.4x | n/a | €138.1m |
A8D AB Science | n/a | -16.41% | €84.3m |
Price-To-Book vs Peers: A8D has negative equity and a Price-To-Book Ratio (-3.1x) compared to the peer average (1.4x).
Price to Book Ratio vs Industry
How does A8D's PB Ratio compare vs other companies in the DE Pharmaceuticals Industry?
Price-To-Book vs Industry: A8D has negative equity and a Price-To-Book Ratio (-3.1x) compared to the European Pharmaceuticals industry average (2.6x).
Price to Book Ratio vs Fair Ratio
What is A8D's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PB Ratio | -3.1x |
| Fair PB Ratio | n/a |
Price-To-Book vs Fair Ratio: Insufficient data to calculate A8D's Price-To-Book Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | €1.16 | €3.77 +225.00% | 32.63% | €5.00 | €2.54 | n/a | 2 |
| Nov ’26 | €1.16 | €3.77 +226.12% | 32.63% | €5.00 | €2.54 | n/a | 2 |
| Oct ’26 | €1.23 | €3.77 +206.01% | 32.63% | €5.00 | €2.54 | n/a | 2 |
| Sep ’25 | €1.00 | €6.90 +588.12% | 45.03% | €10.00 | €3.79 | €1.19 | 2 |
| Aug ’25 | €0.99 | €6.90 +597.87% | 45.03% | €10.00 | €3.79 | €1.47 | 2 |
| Jul ’25 | €1.08 | €6.90 +538.43% | 45.03% | €10.00 | €3.79 | €1.42 | 2 |
| Jun ’25 | €1.92 | €6.90 +258.37% | 45.03% | €10.00 | €3.79 | €1.19 | 2 |
| May ’25 | €1.90 | €6.90 +262.13% | 45.03% | €10.00 | €3.79 | €1.41 | 2 |
| Apr ’25 | €2.54 | €6.90 +171.99% | 45.03% | €10.00 | €3.79 | €1.32 | 2 |
Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.
Discover undervalued companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/11/17 11:13 |
| End of Day Share Price | 2025/11/14 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
AB Science S.A. is covered by 5 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Michael Ryskin | BofA Global Research |
| Keay Nakae | Chardan Capital Markets, LLC |
| Jean-Pierre Loza | In Extenso Financement & Marché |